These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Cyclometalated Palladium(II) N-Heterocyclic Carbene Complexes: Anticancer Agents for Potent In Vitro Cytotoxicity and In Vivo Tumor Growth Suppression. Fong TT; Lok CN; Chung CY; Fung YM; Chow PK; Wan PK; Che CM Angew Chem Int Ed Engl; 2016 Sep; 55(39):11935-9. PubMed ID: 27571430 [TBL] [Abstract][Full Text] [Related]
9. Iridium(III) carbene complexes as potent girdin inhibitors against metastatic cancers. Ruan ML; Ni WX; Chu JCH; Lam TL; Law KC; Zhang Y; Yang G; He Y; Zhang C; Fung YME; Liu T; Huang T; Lok CN; Chan SL; Che CM Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2316615121. PubMed ID: 38861602 [TBL] [Abstract][Full Text] [Related]
10. Dinuclear Rhenium(I) Tricarbonyl Complexes as Anticancer Drug Candidates. Montesdeoca N; Borkar RL; Sathiyendiran M; Karges J Chemistry; 2024 Jun; 30(32):e202400217. PubMed ID: 38574234 [TBL] [Abstract][Full Text] [Related]
11. The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers. Collery P; Veena V; Harikrishnan A; Desmaele D Invest New Drugs; 2019 Oct; 37(5):973-983. PubMed ID: 30632005 [TBL] [Abstract][Full Text] [Related]
12. Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes as Lysosome-Targeted Anticancer Agents. Yang Y; Guo L; Tian Z; Gong Y; Zheng H; Zhang S; Xu Z; Ge X; Liu Z Inorg Chem; 2018 Sep; 57(17):11087-11098. PubMed ID: 30133276 [TBL] [Abstract][Full Text] [Related]
13. Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs. Liu W; Gust R Chem Soc Rev; 2013 Jan; 42(2):755-73. PubMed ID: 23147001 [TBL] [Abstract][Full Text] [Related]
14. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway. Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763 [TBL] [Abstract][Full Text] [Related]
15. Design of Rhenium Compounds in Targeted Anticancer Therapeutics. Collery P; Desmaele D; Vijaykumar V Curr Pharm Des; 2019; 25(31):3306-3322. PubMed ID: 31475892 [TBL] [Abstract][Full Text] [Related]
17. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity. Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671 [TBL] [Abstract][Full Text] [Related]
18. N-Heterocyclic carbene metal complexes in medicinal chemistry. Oehninger L; Rubbiani R; Ott I Dalton Trans; 2013 Mar; 42(10):3269-84. PubMed ID: 23223752 [TBL] [Abstract][Full Text] [Related]
19. N-heterocyclic carbene metal complexes as bio-organometallic antimicrobial and anticancer drugs. Patil SA; Patil SA; Patil R; Keri RS; Budagumpi S; Balakrishna GR; Tacke M Future Med Chem; 2015; 7(10):1305-33. PubMed ID: 26144266 [TBL] [Abstract][Full Text] [Related]
20. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer. Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY Mol Cancer Ther; 2015 Feb; 14(2):407-18. PubMed ID: 25519702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]